Wall Street is positive on Fate Therapeutics Inc (FATE). On average, analysts give the stock a Strong Buy rating. The average price target is $103.866, which means analysts expect the stock to rise by 69.30% over the next twelve months. That average ranking earns the stock an Analyst Rating of 63, which is better than 63% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating FATE a Strong Buy today. Find out what this means to you and get the rest of the rankings on FATE!